The U.S. Court of Appeals for the Federal Circuit has denied a motion from Indivior (OTCPK:INVVY -5.2%) for a rehearing to reinstate the preliminary injunction against Dr. Reddy's Laboratories (RDY +0.7%) stopping it from marketing a generic version of opioid dependence treatment Suboxone (buprenorphine/naloxone) Sublingual Film.
The ruling is not a judgement in the ongoing patent infringement litigation.
Aquestive Therapeutics (AQST +5.1%) is the sole and exclusive manufacturer of the brand and authorized generic versions and expects to continue making and delivering a "significant volume" of Suboxone this year to licensee Indivior.
Now read: AVEO Pharmaceuticals Gets Sideswiped »
Subscribe for full text news in your inbox